<p>(<b>A</b>) Cells were pretreated with cPGI<sub>2</sub> followed by GFs. (<b>B</b>) VSMCs were transfected with 14-3-3β, η or θ siRNA or a control scRNA and the respective 14-3-3 proteins were analyzed. (<b>C</b>) VSMCs transfected with siRNA of 14-3-3β, η or θ were treated with cPGI<sub>2</sub> (100 µM) and GFs. SM22α and Calponin-1 in cell lysates were analyzed by Western blotting. (<b>D</b>) VSMCs were transfected with Flag-tagged 14-3-3β or θ vectors. Following GFs treatment, cells were lysed and SM22α was determined by Western blotting. All blots are representative of n≥3. (<b>E</b>) A schematic illustration of the role of PGI<sub>2</sub>/PPARα/14-3-3β and θ in controlling VSMC apoptosis and contractile phenotype.</p
<p>VSMCs were treated with 48 h adenovirus infection, then incubated with 0.4 mmol/L OA for 24 h. PG...
<p>In (A), Con, VSMCs were cultured without any treatment; ATV, VSMCs were treated only with atorvas...
UMR106 cells were treated without and with PKC inhibitors Calphostin C (A) or Gö6976 (B, C) at the i...
<div><p>We hypothesized that prostacyclin (PGI<sub>2</sub>) protects vascular smooth muscle cell (VS...
We hypothesized that prostacyclin (PGI2) protects vascular smooth muscle cell (VSMC) against apoptos...
<p>VSMCs were transfected with siRNA S1 or the negative control (siRNA N). The interference effect w...
<p>A) OV2008 cells were transiently transfected with full-length cyclin G2 (CCNG2-V5), PEST-24, or Δ...
[[abstract]]We hypothesized that prostacyclin (PGI2) protects vascular smooth muscle cell (VSMC) aga...
[[abstract]]We hypothesized that prostacyclin (PGI2) protects vascular smooth muscle cell (VSMC) aga...
<p>VSMCs transfected with siRNA (SI) or the negative control (N), were either left untreated or stim...
<p>VSMCs were transfected with siRNA (SI) or the negative control (N), then left stimulated with 15 ...
<p>PSCs were transfected with negative control and β-catenin siRNA. (A) Transfection efficiency of P...
<p>(A) HeLa cells were transfected with 40 nM PSPC1 siRNAs (siPSPC1) or control siRNA (siControl) (‘...
Atherosclerosis and restenosis are proliferative vascular diseases involving, in part, deregulated v...
Atherosclerosis and restenosis are proliferative vascular diseases involving, in part, deregulated v...
<p>VSMCs were treated with 48 h adenovirus infection, then incubated with 0.4 mmol/L OA for 24 h. PG...
<p>In (A), Con, VSMCs were cultured without any treatment; ATV, VSMCs were treated only with atorvas...
UMR106 cells were treated without and with PKC inhibitors Calphostin C (A) or Gö6976 (B, C) at the i...
<div><p>We hypothesized that prostacyclin (PGI<sub>2</sub>) protects vascular smooth muscle cell (VS...
We hypothesized that prostacyclin (PGI2) protects vascular smooth muscle cell (VSMC) against apoptos...
<p>VSMCs were transfected with siRNA S1 or the negative control (siRNA N). The interference effect w...
<p>A) OV2008 cells were transiently transfected with full-length cyclin G2 (CCNG2-V5), PEST-24, or Δ...
[[abstract]]We hypothesized that prostacyclin (PGI2) protects vascular smooth muscle cell (VSMC) aga...
[[abstract]]We hypothesized that prostacyclin (PGI2) protects vascular smooth muscle cell (VSMC) aga...
<p>VSMCs transfected with siRNA (SI) or the negative control (N), were either left untreated or stim...
<p>VSMCs were transfected with siRNA (SI) or the negative control (N), then left stimulated with 15 ...
<p>PSCs were transfected with negative control and β-catenin siRNA. (A) Transfection efficiency of P...
<p>(A) HeLa cells were transfected with 40 nM PSPC1 siRNAs (siPSPC1) or control siRNA (siControl) (‘...
Atherosclerosis and restenosis are proliferative vascular diseases involving, in part, deregulated v...
Atherosclerosis and restenosis are proliferative vascular diseases involving, in part, deregulated v...
<p>VSMCs were treated with 48 h adenovirus infection, then incubated with 0.4 mmol/L OA for 24 h. PG...
<p>In (A), Con, VSMCs were cultured without any treatment; ATV, VSMCs were treated only with atorvas...
UMR106 cells were treated without and with PKC inhibitors Calphostin C (A) or Gö6976 (B, C) at the i...